Xerox University Microfilms 300 North Zeeb Road Ann Arbor, Michigan 48106 73-30,250

Total Page:16

File Type:pdf, Size:1020Kb

Xerox University Microfilms 300 North Zeeb Road Ann Arbor, Michigan 48106 73-30,250 CHEMICAL CONSTITUENTS OF ARTEMISIA FILIFOLIA (TORR.) Item Type text; Dissertation-Reproduction (electronic) Authors Torrance, Sterling Jay, 1943- Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 05/10/2021 04:38:05 Link to Item http://hdl.handle.net/10150/290336 INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You will find a good image of the page in the adjacent frame. 3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete. 4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation. Silver prints of "photographs" may be ordered at additional charge by writing the Order Department, giving the catalog number, title, author and specific pages you wish reproduced. 5. PLEASE NOTE: Some pages may have indistinct print. Filmed as received. Xerox University Microfilms 300 North Zeeb Road Ann Arbor, Michigan 48106 73-30,250 TORRANCE, Sterling Jay, 1943- CHEMICAL CONSTITUENTS OF ARTEMISIA FILIFOLIA TORR. The University of Arizona, Ph.D., 1973 Chemistry, organic l University Microfilms, A XEROX Company , Ann Arbor, Michigan THTS riTSSRRTATION HAS BEEN MICROFILMED EXACTLY AS RECEIVED. CHEMICAL CONSTITUENTS OF ARTEMISIA FILIFOLIA TORR. by Sterling Jay Torrance A Dissertation Submitted to the Faculty of the DEPARTMENT OF CHEMISTRY In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 19 7 3 THE UNIVERSITY OF ARIZONA. GRADUATE COLLEGE I hereby recommend that this dissertation prepared under my direction by Sterling Jay Torrance entitled CHEMICAL CONSTITUENTS OF ARTEMISIA FILIFOLIA TORR. be accepted as fulfilling the dissertation requirement of the degree of DOCTOR OF PHILOSOPHY 7A/73 Dissertation Director Date After inspection of the final copy of the dissertation, the following members of the Final Examination Committee concur in its approval and recommend its acceptance:"" ^/•73 tHfvvC/ Urt ' This approval and acceptance is contingent on the candidate's adequate performance and defense of this dissertation at the final oral examination. The inclusion of this sheet bound into the library copy of the dissertation is evidence of satisfactory performance at the final examination. t STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of requirements for an advanced degree at The University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that accurate acknowledgment of source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his judgment the proposed use of the material is in the interests of scholarship. In all other instances, however, permission must be obtained from the author. SIGNED: ACKNOWLEDGMENTS The author wishes to express his gratitude to Drs. C. Steelink, the director of this research, T. A. Geissman, J. Wolinsky, and R. G. Carlson for assistance during the course of this work. The author is especially grateful for financial assistance in the forms of a National Science Foundation Summer Traineeship (Summer, 1971), Atlantic Richfield Company Fellowship (I Semester, 1971-72), and a University of Arizona Predoctoral Fellowship (II Semester, 1972-73). iii TABLE OF CONTENTS Page LIST OF ILLUSTRATIONS viii LIST OF TABLES . X ABSTRACT xi INTRODUCTION 1 { RESULTS AND DISCUSSION 4 A. filifolia Monoterpene Lactones 4 Minor Monoterpene Constituents of A. filifolia 32 Other Constituents of A.' filifolia 36 BIOSYNTHETIC IMPLICATIONS 43 EXPERIMENTAL 59 Collection of the Plant Material 60 Steam Distillation of the Plant Material 60 Fractional Distillation of the Steam Distillate 61 Hydrolysis of the A. filifolia Lactones 12 and 13; Isolation of Hydroxy-acids W and M . 61 FractionaT^Crystallization of 17 and 18 64 Regeneration of Lactone 12 from^the Hydroxy-acid 17 . 66 Regeneration oflactone 13 from the Hydroxy^HCid 13 •••••••••••••••• 66 Preparation of i^enchone Oxime (Figure 4) 67 Acid Ifydrolysis of Fenchone Oxime; oc- and P-Fencholenic Acid Nitriles (Figure 4) 68 Selective Saponification of the Mixture of a- and P-Fencholenic Acid Nitriles; 3- Fencholenic Acid and a-Fencholenic Acid Amide (Figure 4) 69 Hydrolysis of a-Fencholenic Acid Amide; a-Fencholenic Acid (Figure 4) 71 Preparation of Geranic Acid (Figure 4) 72 Preparation of (jO-Filifolone (Figure 4) 74 iv V TABLE OF CONTENTS—Continued Page Hydrolysis of Filifolone; a-Fencholenic Acid (Figure 4) 75 Iodolactone of a-Fencholenic Acid (Figure 4) . 75 Dehydroiodination of a-Fencholenic Acid Iodolactone; Preparation of Lactone 2 (Figure 4) m 76 Hydrogenolysis of A. filifolia Lactones 12 and 13; Preparation of Carboxylic Acids' 9 ancPlO 78 Preparation of a-Cyclogeranic Acid (5) 79 Hydrogenation of the Carboxylic Acid Mixture 9+10 from A. filifolia; Preparation of 1f;he Carboxylic Acid 11 81 Preparation of 2,4-Dime^hyl-l,3-pentadiene (Figure 5) 83 Preparation of the Carboxylic Acid 9 (Figure 5) ? 84 Hydrolysis of Chrysanthenone; Preparation of Carboxylic Acid 9 (Figure 5) 85 Hydrogenation of Synthetic 9; Preparation of Carboxylic Acid 11 (Figure 5) 86 Methanolysis of the^A. filifolia Lactone (12 + 13) Mixture; Preparation of 19 88 Oxi$ationwof 19; Preparation of the Keto-acid 89 Photolysis of^Verbenone; Preparation of Chrysanthenone (Figure 8) 90 Oxidation of Chrysanthenone; Chrysanthenone Epoxide (Figure 8) 93 Solvolysis of Chrysanthenone Epoxide; Preparation of the Acid 17 (Figure 8) 95 Thermal Rearrangement of Chrysanthenone Epoxide; Preparation of Lactone 12 (Figures 8 and 9) T 96 Bromination of the Acid 9; Preparation of Lactone 12 (Figure 10 )w 96 Photolysis^of Chrysanthenone; Preparation of the Ketone 22 (Figure 11) 98 Oxidation of Preparation of Epoxide 23 (Figure ll)MMtt ^ ... 101 Thermal Rearrangement of Epoxide 23; Preparation of Lactone 13 (Figure 11) 104 Solvolysis of Epoxide 23 ^Preparation of Hydroxy-acid 18 (Figure 11) 106 Preparation of Methyl—2-butenoic Acid (Senecioic Acid, p,0-Dimethylacrylic Acid) (Figure 12) 107 vi TABLE OF CONTENTS—Continued Page Attempted Lewis Acid-catalyzed Diels-Alder Reaction of Senecioic Acid and Isoprene (Figure 12) 108 Preparation of Ethyl 3-Methyl-2-butenoic Acid (Ethyl Senecioate) 109 Attempted Lewis Acid-catalyzed Diels-Alder Reaction of Ethyl Senecioate and Isoprene (Figure 12) Ill Performic Acid Oxidation of 9; Preparation of Lactone 28 (Figure 13) . .m 112 Iodolactonization of the Carboxylic Acid 9; Preparation of Iodolactone 30 (Figure l^f) ... 113 WAAj4 Preparative GLC of the A. filifolia Steam Distillate; Isolation of the Mixture of Lactones 12+13 114 Preparative^^LC o¥ Lactone 12; Isolation of the Mixture of Lactones l^w+ 13 115 TTHeating of_ TLactone . 12T „ mm mm 115 Steam Distillation ol Lactone 12 116 Steam Distillation of 17; Isolation of the Mixture of Lactones 1'$ + 13 116 Photolysis of ( + )-Verbenone'f^Obtention of (+)-Chrysanthenone (Figure 8) 117 Oxidation of (+)-Chrysanthenone; Preparation of (-)-Chrysanthenone Epoxide (Figure 8) . 118 Thermolysis of (-)-Chrysanthenone Epoxide; Preparation of (-)-Lactone 12 (Figure 8) . 119 Hydrolysis of (-)-Chrysanthenone Epoxide; Preparation of (+)-17 (Figure 8) 119 Preparative GLC of the A. filifolia Steam Distillate; Isolation of (-)-Verbenone, Borneol Piperitenone, and the Enedione 34 (Figure 15) 120 Preparation of (+)-Verbenone 2,4- Dinitrophenylhydrazone 122 Preparation of Piperitenone 2,4- Dinitrophenylhydrazone 123 Preparation of [3-Isophorone (Figure 17) 123 Preparation of 4-Hydroxy-3,5,5-trimethylcyclohex- 2-en-l-one (Figure 17)..... 125 Oxidation of 4-Hydroxy-3,5,5-trimethylcyclohex- 2-en-l-one; Preparation of the Ene-dione 34 (Figure 17) T.
Recommended publications
  • Hydantoin and Succinimide-Substituted
    (1 9) J Eur°Pean Patent Office <*S Office europeen des brevets (11) EP 0 533 243 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) int. CI.6: C07D 401/1 2, C07D 471/10, of the grant of the patent: A61 K 31/445 Q07D 401 /1 4 17,2,997 Buiietin 1997/51 // (C07D471/1 0, 235:00, (21) Application number: 92202723.0 221:00) (22) Date of filing: 08.09.1992 (54) Hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives Hydantoin und Succinimid-substituierte Spiroindanylcamphorsulfonyl als Oxytocin-Antagonisten Derives de spiroindanylcamphorsulfonyl substitues par un radical hydantoine ou succinimide comme antagonists d'oxytocine (84) Designated Contracting States: (74) Representative: CH DE FR GB IT LI NL Thompson, John Dr. et al Merck & Co., Inc. (30) Priority: 16.09.1991 US 760416 European Patent Department Terlings Park (43) Date of publication of application: Eastwick Road 24.03.1993 Bulletin 1993/12 Harlow, Essex CM20 2QR (GB) (73) Proprietor: Merck & Co., Inc. (56) References cited: Rahway New Jersey 07065-0900 (US) EP-A- 0 444 945 EP-A- 0 445 974 EP-A- 0 450 761 EP-A- 0 486 280 (72) Inventors: US-A- 3 654 287 • Gilbert, Kevin Bally, PA 19503 (US) • EP-A- 0 444 945 • Williams, Peter D. • EP-A- 0 445 974 Harleysville, PA 19438 (US) • EP-A- 0 450 761 • Hobbs, Doug W. • EP-A- 0 486 280 Lansdale, PA 19446 (US) • US-A- 3 654 287 • Evans, Ben E. Lansdale, PA 19446 (US) Remarks: • Veber, Daniel F. The file contains technical information submitted Ambler, PA 19002 (US) after the application was filed and not included in this specification CO CO CM CO CO Note: Within nine months from the publication of the mention of the grant of the European patent, give IO any person may notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Calcium Channel Blocker As a Drug Candidate for the Treatment of Generalised Epilepsies
    UNIVERSITAT DE BARCELONA Faculty of Pharmacy and Food Sciences Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies Final degree project Author: Janire Sanz Sevilla Bachelor's degree in Pharmacy Primary field: Organic Chemistry, Pharmacology and Therapeutics Secondary field: Physiology, Pathophysiology and Molecular Biology March 2019 This work is licensed under a Creative Commons license ABBREVIATIONS AED antiepileptic drug AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ANNA-1 antineuronal nuclear antibody 1 BBB blood-brain barrier Bn benzyl BnBr benzyl bromide BnNCO benzyl isocyanate Boc tert-butoxycarbonyl Bu4NBr tetrabutylammonium bromide Ca+2 calcium ion CACNA1 calcium channel voltage-dependent gene cAMP cyclic adenosine monophosphate CCB calcium channel blocker cGMP cyclic guanosine monophosphate CH3CN acetonitrile Cl- chlorine ion Cmax maximum concentration CMV cytomegalovirus CTScan computed axial tomography DCM dichloromethane DIPEA N,N-diisopropylethylamine DMF dimethylformamide DMPK drug metabolism and pharmacokinetics DNET dysembryoplastic neuroepithelial tumours EEG electroencephalogram EPSP excitatory post-synaptic potential FDA food and drug administration Fe iron FLIPR fluorescence imaging plate reader fMRI functional magnetic resonance imaging GABA γ-amino-α-hydroxybutyric acid GAD65 glutamic acid decarboxylase 65 GAERS generalised absence epilepsy rat of Strasbourg GluR5 kainate receptor GTC generalised tonic-clonic H+ hydrogen ion H2 hydrogen H2O dihydrogen dioxide (water)
    [Show full text]
  • A Coniparative Evaluation of Operating Conditions for the Electrochemical Bromination and Chlorination of Succinimide
    Bulletin of Electrochemistry 16 (12) December 2000, pp 544-550 0256-1654/2000/$ 3-50 © 2000 CECRI • A CONIPARATIVE EVALUATION OF OPERATING CONDITIONS FOR THE ELECTROCHEMICAL BROMINATION AND CHLORINATION OF SUCCINIMIDE S KRISHNAMOORTHY, R KANAKAM SRINIVASAN AND M NOEL Central Electrochemical Research Institute, Karaikudi 630 006. INDIA [Received: 20 September 1998 Accepted: 19 September 2000] Platinum was found to be the electrode of choice for both electrochlorination and bromination of succinimide leading to the formation of N chloro succinimide (NCS) and N bromo succinimide (NBS) respectively. Because of the competitive processes 150% and 285% of theoretical charge has to be passed for bromination and chlorination respectively. 12% (w!v) of succinimide could be used for bromination while only 2% (w!v) of this reactant is optimum for chlorination. Optimum conditions have been evaluated for the process. A maximum yield of 55% and 88% could be achieved for bromination and chlorination of succinimide respectively. Keywords: •Chlorination, bromination succinimide INTRODUCTION A thermostated closed glass vessel with provIsions for working electrode (platinum, graphite, TSIA and GSLD) Probably because of the facile bromination [1-4] and [14-15], counter electrode, platinum (4 x 3 ems) chlorination [5-9] of succinimide (SI) by chemical means, thermometer and a glass stirrer was used as the the corresponding electrohalogenation process have not preparative cell. received considerable attention. A brief report on the After completion of electrolysis, NCS and NBS are preparation of N- bromosuccinimide (NBS) in aqueous separated by filtration and washed with a cold (275 K) sodium bromide solution on platinum electrode is saturated solution of the corresponding N-halosuccinimide.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • United States Patent 19 L L 3,928,456 Kováts Et Al
    United States Patent 19 l l 3,928,456 Kováts et al. (45) Dec. 23, 1975 (54) CYCLOALPHATIC UNSATURATED 260/488 H; 260/.514 J; 260/.530 N; 260/544 L; KETONES AS ODOUR AND 260/546; 260/586 C; 260/586 F; 260/586 P; TASTE-MODIFYING AGENTS 260/595; 260/598; 260/601 R; 260/617 R; (75) Inventors: Ervin Kováts, Lausanne; Edouard 260/617 E; 260/617 F; 260/632 Y; 260/638 R; Demole, Geneva; Cinther Ohloff, 260/638 Y; 260/642; 260/666 R; 426/155; Bernex,Geneva, Switzerland; Max 426/170; 426/175; 426/190; 426/192; Stoll, deceased, late of Lully, 426/193; 426/213; 426/214; 426/221; 426/229 Geneva, Switzerland, by Suzanne (51) int. Cl’.......................................... CO7C 49/61 Stoll, executrix 58 Field of Search................................. 260/586 R 73 Assignee: Firmenich S.A., Geneva, 56) References Cited Switzerland OTHER PUBLICATIONS 22) Filed: Sept. 6, 1974 Demole et al., “Helv. Chim. Acta.,' Vol. 53, Fasc. 21 Appl. No.: 503,794 3(1970) pp. 541-551. Related U.S. Application Data Primary Examiner-Norman Morgenstern 60 Division of Ser. No. 35,594, May 7, 1970, Attorney, Agent, or Firm-Pennie & Edmonds abandoned, which is a continuation-in-part of Ser. No. 774,179, Nov. 7, 1968, abandoned. 57 ABSTRACT New cycloaliphatic unsaturated ketones and their use (30) Foreign Application Priority Data as perfuming and odour-modifying agents in the man Nov. 9, 1967 Switzerland....................... 5667/67 ufacture of perfumes and perfumed products, and as Nov. 1, 1968 Switzerland....................... 16309/68 flavouring and taste-modifying agents in the prepara May 7, 1969 Switzerland........................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Antimicrobial & Anticonvulsant Activity Show Some Newer Phthalimide
    International Journal of Science and Research (IJSR) ISSN (Online): 2319-7064 Index Copernicus Value (2016): 79.57 | Impact Factor (2017): 7.296 Antimicrobial & Anticonvulsant Activity Show Some Newer Phthalimide Derivatives Deepika Pal M-Pharma (Pharmacology), Department of Pharmacology –Krishna College of Pharmacy, Noorpur Moradabad, Bijnor (Uttar Pradesh) Abstract: The aim of the study was to design, synthesize and investigate the antimicrobial & fungal activity of some α N-Phthilimido derivatives of amino acids by Srinivasan et al;2010. The chemical structures of the titled compound were confirmed by IR, 13CNMR and elemental analysis. All the compounds are screened for antimicrobial activity against gram positive, gram negative bacteria (Escherichia coli, Klebsiella, Staphylococcus epidermitis, Bacillus cereus, Micrococcus leteus, Staphylococcus aureus) and fungal strains (Candida albicans, Aspergillus niger). Synthetic heterocyclic compounds have been found to possess important biological properties including anticonvulsant effects in man and animals. This study was aimed at highlighting the anticonvulsant properties of two phthalimide derivatives (N cyclopentylphthalimide and Nbenzylphthalimide). N-Cyclopentylphthalimide and N-benzylphthalimide were synthesized by Iniaghe et al; 2010 and screened for anticonvulsant properties using adult Swiss mice. Convulsion was induced using maximum electroshock therapy. Keywords: 13CNMR, Staphylococcus aureus, electroshock therapy, α N-Phthilimido derivative 1. Introduction alpha 2 delta (α2δ). And the types of seizure are shown in table 1. The anticonvulsants are a diverse group of pharmaceuticals used in the treatment of epileptic seizures. Anticonvulsants Drugs are also increasingly being used in the treatment of bipolar Aldehydes:Paraldehyde disorder, since many seem to act as mood stabilizers. The Aromatic allylic alcohols:Stiripentol goal of an anticonvulsant is to suppress the rapid and Barbiturates: Phenobarbital, Methylphenobarbital, excessive firing of neurons that start a seizure.
    [Show full text]
  • University of Glasgow Studies in The
    UNIVERSITY OF GLASGOW STUDIES IN THE CYCLOHEPTANE FIELD By: J. R. B. Campbell, B.Sc. Thesis submitted for the Degree of Ph.D. Supervisor: Professor R. A. Raphael June, 1956. ProQuest N um ber: 13849064 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13849064 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 STUDIES IN THE CYCLOHEPTANE FIELD Part I: POSSIBLE ROUTES TO AZATROPOLONES Part II: ELABORATION PRODUCTS OF EUCARVONE Part III: A SYNTHESIS OF THUJIC ACID ACKNOWLEDGEMENTS Microanalyses were carried out by Mr. J. M. L. Cameron and Miss Christie in Glasgow, and by Mr. J. G. Henry and Mr. J. Austin in Belfast. Microhydrogenations are due to Mr. J. M. L. Cameron. Ultra-violet absorption spectra were determined by Mr. J. Austin with a Unicam SP500 Spectrophotometer and infra- red spectra by Dr. G. Eglinton with a Perkin-Elmer Model 21 Spectrophotometer. Melting-points throughout are uncorrected. The author wishes to thank the Department of Scientific and Industrial Research, and the Queen1s University of Belfast, for providing grants which enabled this work to be undertaken.
    [Show full text]
  • Federal Register / Vol. 60, No. 125 / Thursday, June 29, 1995 / Rules and Regulations 34039
    Federal Register / Vol. 60, No. 125 / Thursday, June 29, 1995 / Rules and Regulations 34039 List of Subjects in 33 CFR Part 151 action will help to ensure that Coast industry. This action merely serves to Administrative practice and Guard requirements are current and that remove needless entries from the Coast procedure, Oil pollution, Penalties, the hazardous materials tables and lists Guard's lists and tables. Further, the Reporting and recordkeeping are free of entries that unnecessarily public was provided an opportunity to requirements, Water pollution control. complicate the Coast Guard's comment on this action in the ANPRM For the reasons set out in the regulations. published on August 31, 1994. In the preamble, the Coast Guard amends 33 EFFECTIVE DATE: This rule is effective on ANPRM, the Coast Guard proposed CFR part 151 as follows: August 28, 1995. commodities for deletion, and asked ADDRESSES: Unless otherwise indicated, whether anyone had information on PART 151ÐVESSELS CARRYING OIL, documents referred to in this preamble these commodities, or any other NOXIOUS LIQUID SUBSTANCES, are available for inspection or copying commodities that might be appropriate GARBAGE AND MUNICIPAL OR at the office of the Executive Secretary, for deletion as well. Four comments COMMERCIAL WASTE, AND BALLAST Marine Safety Council (G±LRA/3406) were received and are addressed in this WATER (CGD 95±900), U.S. Coast Guard rulemaking. Accordingly, the Coast Headquarters, 2100 Second Street, NW., Guard finds that good cause exists 1. The authority citation for part 151, under 5 U.S.C. 553(b) to publish this subpart A, continues to read as follows: room 3406, Washington, DC 20593± 0001 between 8 a.m.
    [Show full text]
  • Uhm Phd 9615509 R.Pdf
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality ofthis reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affectreproduction. In the unlikely. event that the author did not send UMI a complete mam1script and there are missing pages, these will be noted. Also, if unauthorized copyrightmaterial had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continning from left to right in equal sectionswith small overlaps. Each original is also photographed in one exposure and is included in reducedform at the back ofthe book. Photographs included in the original mamJscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell mtormanon Company 300 North Zeeb Road. Ann Arbor. MI48106-1346 USA 313/761-4700 800:521-0600 PART I: SYNTHESIS OF 7-CIS CONTAINING 3-DEHYDRORETINAL ISOMERS AND THEIR BINDING PROPERTIES WITH BOVINE OPSIN PART II: SYNTHESIS AND PROPERTIES OF A SERIES OF LOWER HOMOLOGS OF B-CAROTENE A DISSERTATION SUBMITTED TO THE GRADUATE DIVISION OF THE UNIVERSITY OF HAWAII IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN CHEMISTRY DECEMBER 1995 By Rongliang Chen Dissertation Committee: Robert S.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Ep 3480202 A1
    (19) TZZ¥Z Z _T (11) EP 3 480 202 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.05.2019 Bulletin 2019/19 C07D 498/14 (2006.01) A61K 39/395 (2006.01) A61K 51/00 (2006.01) A61K 47/50 (2017.01) (21) Application number: 18196502.1 (22) Date of filing: 02.06.2010 (84) Designated Contracting States: • SINGH, Rajeeva AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Framingham, MA Massachusetts 01701 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • CHARI, Ravi, V., J. PL PT RO SE SI SK SM TR Newton, MA Massachusetts 02161 (US) Designated Extension States: BA ME RS (74) Representative: Miller, David James et al Mathys & Squire LLP (30) Priority: 03.06.2009 US 18377409 P The Shard 32 London Bridge Street (62) Document number(s) of the earlier application(s) in London SE1 9SG (GB) accordance with Art. 76 EPC: 10783998.7 / 2 437 790 Remarks: •Claims filed after the date of filing of the application (71) Applicant: ImmunoGen, Inc. (Rule 68(4) EPC). Waltham, MA 02451 (US) •This application was filed on 25-09-2018 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • KELLOGG, Brenda A. Medford, MA Massachusetts 02155 (US) (54) CONJUGATION METHODS (57) This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent.
    [Show full text]